Article citationsMore>>

André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F. and de Gramont, A. (2009) Improved Overall Survival with Oxaliplatin, Fluorouracil and Leucovorin as Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. Journal of Clinical Oncology, 27, 3109-3116.
http://dx.doi.org/10.1200/JCO.2008.20.6771

has been cited by the following article:

• TITLE: Oxaliplatin Induced Neurotoxicity among Patients with Colorectal Cancer: Documentation in Medical Records—A Pilot Study

  AUTHORS: Jenny E. Drott, Hans Starkhammar, Sussanne Börjeson, Carina M. Berterö

  KEYWORDS: Adjuvant Oxaliplatin Chemotherapy; Colorectal Cancer; Medical Record Review; Neurotoxicity; Summative Content Analysis

  JOURNAL NAME: Open Journal of Nursing, Vol.4 No.4, April 9, 2014

  ABSTRACT: Patients with colorectal cancer (CRC) can have chemotherapy with oxaliplatin postoperatively. Oxaliplatin can cause acute and chronic neurotoxicity. It is important to be aware of neurotoxic side effects so they can be documented and action taken at an early stage. The study aimed to identify and explore neurotoxic side effects documented in the medical records of patients with colorectal cancer treated with oxaliplatin-based adjuvant chemotherapy. Data in this study were medical records; presenting documentation about patients treated at the University Hospital in the south of Sweden between 2009 and 2010. A summative content analysis approach was used to explore the neurotoxic side effects. Identification and quantification of the content of medical records were carried out by using a study-specific protocol. “Cold sensitivity” and “tingling in the hands” were the most frequently documented neurotoxicity-related terms in the medical records. This identification was followed by interpretation. Three categories were identified in the interpretive part of the study: acute, chronic, and degree of neurotoxicity. The results show the importance of awareness of neurotoxic side effects so that they can be documented and action taken at an early stage. The documentation could be more reliable if patient-reported structured measurements were used, combined with free descriptions in the medical records. Being able to follow the progression of the symptoms during and after treatment would improve patient’s safety and also quality of life. The protocol that we developed and used in this review of medical records may be helpful to structure the documentation in the electronic system for documentation of neurotoxicity side effects.